{"title":"Prussian Blue Nanoparticles Promoting Diabetic Bone Regeneration via Mitochondrial Recovery.","authors":"Anqi Gu, An Lao, Weiqi Li, Ziyang Liu, Chuang Zhou, Jianqiang Cai, Qiang Chen, Kaili Lin, Lijuan Song, Xiangbing Wu, Jiaqiang Liu","doi":"10.34133/bmef.0204","DOIUrl":"10.34133/bmef.0204","url":null,"abstract":"<p><p><b>Objective:</b> This work aims to develop Prussian blue (PB) nanoparticles that mitigate bone marrow mesenchymal stem cell (BMSC) senescence and alleviate bone loss in type 2 diabetes (T2D). <b>Impact Statement:</b> PB nanozymes are established as a targeted therapeutic strategy for maintaining bone quality in T2D-addressing an unmet clinical need through innovative nanomaterial design. <b>Introduction:</b> Diabetes is associated with a higher risk of fractures through distinct mechanisms. Elevated blood sugar levels and excessive nutrition in T2D trigger reactive oxygen species (ROS) overproduction that impairs mitochondrial function, induces BMSC senescence, and compromises osteogenic potential. Engineered as artificial enzyme counterparts, nanozymes effectively eliminate ROS while circumventing the inherent constraints of natural antioxidant enzymes. <b>Methods:</b> PB nanoparticles were synthesized and fully characterized. BMSCs treated with high glucose plus palmitate-bovine serum albumin served as the diabetic cell model. The nanoparticles were evaluated for their capacity to scavenge ROS, modulate mitochondrial function, counteract cellular senescence, and restore osteogenic potential. Finally, their ability to attenuate bone loss was verified in a T2D mouse model. <b>Results:</b> We demonstrated that PB nanoparticles efficiently scavenge ROS, rebalance mitochondrial dynamics by up-regulating fusion proteins and down-regulating fission proteins, and restore membrane potential. These actions suppress BMSC senescence and revive osteogenic capacity, culminating in substantial attenuation of T2D-associated bone loss in vivo. <b>Conclusion:</b> These findings introduce a promising and innovative approach for managing bone quality in patients with T2D.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0204"},"PeriodicalIF":7.7,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12719558/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145822182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-12-16eCollection Date: 2025-01-01DOI: 10.34133/bmef.0211
Shaojun Liu, Qing Xia, Yuwei Du, Tingting Yu, Dongyu Li, Dan Zhu
{"title":"Transmissive-Detected Hyperspectral Imaging for Single-Vessel-Resolution Blood Oxygen Mapping.","authors":"Shaojun Liu, Qing Xia, Yuwei Du, Tingting Yu, Dongyu Li, Dan Zhu","doi":"10.34133/bmef.0211","DOIUrl":"10.34133/bmef.0211","url":null,"abstract":"<p><p><b>Objective:</b> This study proposed a transmissive-detected hyperspectral imaging (TD-HSI) strategy for blood oxygen mapping in order to address the limitation of reflective HSI in obtaining high-resolution blood oxygen information from deep tissues. <b>Impact Statement:</b> This innovative TD-HSI has great potential in promoting noninvasive, high-resolution in vivo blood oxygen monitoring and provides a powerful tool for the study of tissue oxygenation and microcirculation diseases. <b>Introduction:</b> Oxygen saturation (SO<sub>2</sub>) served as a critical indicator reflecting physiological states. However, strong scattering of tissue prevents accurate SO<sub>2</sub> mapping with promising resolution, which also limited the depth of reflective HSI. <b>Methods:</b> Monte Carlo simulations were employed to theoretically evaluate the deep-tissue measurement of SO<sub>2</sub> between conventional reflective-detected HSI (RD-HSI) and TD-HSI. Then, in vivo TD-HSI system was used to observe the impact of hypoxia on individual arteries and veins at various locations in mice, and monitor the SO<sub>2</sub> fluctuations during subcutaneous tumor growth over a 1-week period. <b>Results:</b> The simulations showed that TD-HSI remarkably extended the depth of accurate SO<sub>2</sub> detection and boasted approximately 6-fold greater precision in detecting SO<sub>2</sub> variations. In vivo experiments validated the efficacy of TD-HSI, demonstrating its capability to achieve SO<sub>2</sub> mapping in mice skin with single-vessel resolution, a feat not possible with RD-HSI. <b>Conclusion:</b> We conducted a comprehensive evaluation of the capability of TD-HSI strategy for deep-tissue blood oxygen imaging. Our data demonstrated that TD-HSI offered substantial improvements over conventional RD-HSI in noninvasively acquiring blood oxygen information in deep tissue.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0211"},"PeriodicalIF":7.7,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707973/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145776387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-12-09eCollection Date: 2025-01-01DOI: 10.34133/bmef.0207
Enakshi D Sunassee, Marcia Cunha Dos Santos, Riley J Deutsch-Williams, Sanjana Sankholkar, Megan Madonna, Gregory Palmer, Nirmala Ramanujam
{"title":"Quantifying Spatiotemporal Heterogeneity of Tumor Metabolism and Vasculature with a Multiparametric Point-of-Investigation Microscope.","authors":"Enakshi D Sunassee, Marcia Cunha Dos Santos, Riley J Deutsch-Williams, Sanjana Sankholkar, Megan Madonna, Gregory Palmer, Nirmala Ramanujam","doi":"10.34133/bmef.0207","DOIUrl":"10.34133/bmef.0207","url":null,"abstract":"<p><p><b>Objective:</b> The aim of this study was to develop and apply a dual-scale Capillary-Cell (CapCell) microscope to quantify spatial and temporal heterogeneity in tumor metabolism and vasculature during anti-angiogenic therapy. <b>Impact Statement:</b> This study introduces a dual-scale CapCell microscope, a novel imaging system to dynamically visualize metabolic and vascular adaptations in vivo. The platform reveals subregional features associated with treatment that are often missed by bulk analyses. <b>Introduction:</b> Tumor recurrence is often driven by microenvironmental heterogeneity in metabolism and perfusion. Given the importance of metabolic reprogramming in treatment response, the dual-scale CapCell microscope was designed to capture widefield and high-resolution images of metabolic-vascular coupling in vivo. <b>Methods:</b> The dual-scale CapCell microscope was implemented to image multiple endpoints including mitochondrial membrane potential and glucose uptake (widefield and high-resolution images) that are colocalized with vessel density and distance between vessels (high resolution). The CapCell was used to image 4T1 tumors grown in an orthotopic window chamber longitudinally following treatment with Combretastatin A-1 (CA1), a vascular-disrupting agent. Imaging was performed over a period of 8 days to evaluate the effects of CA1 administered on days 1 and 5. <b>Results:</b> Treated tumors showed a significant decrease in metabolism and vessel fraction, and a significant increase in the distance between vessels immediately following the first treatment. Within microregional areas, elevated mitochondrial activity was associated with vascular-dense regions, whereas increased glucose uptake was more apparent in less vascularized regions. Interestingly, the second treatment on day 6 had little effect on the tumor metabolism, and in fact, metabolism at this time point recovered to baseline levels despite a persistent reduction in vessel area fraction and no corresponding recovery in vascular proximity. <b>Conclusion:</b> The CapCell enables dual-scale, multiparametric imaging of tumor microenvironments, capturing spatial metabolic and vascular features often linked to poor therapeutic outcomes. This platform can inform therapeutic timing and guide the development of combination strategies by resolving critical tumor subpopulations.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0207"},"PeriodicalIF":7.7,"publicationDate":"2025-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12688417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145727122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-12-02eCollection Date: 2025-01-01DOI: 10.34133/bmef.0206
Christopher Bendkowski, Adam P Levine, Manuel Rodriguez-Justo, Laurence B Lovat, Marco Novelli, Michael Shaw
{"title":"VS-FPM: Large-Format, Label-Free Virtual Histopathology Microscopy.","authors":"Christopher Bendkowski, Adam P Levine, Manuel Rodriguez-Justo, Laurence B Lovat, Marco Novelli, Michael Shaw","doi":"10.34133/bmef.0206","DOIUrl":"10.34133/bmef.0206","url":null,"abstract":"<p><p><b>Objective:</b> This article describes a new method (VS-FPM) for analysis of unstained tissues based on the application of supervised machine learning to generate brightfield hematoxylin and eosin (H&E) images from phase images recovered using Fourier ptychographic microscopy (FPM). <b>Impact Statement:</b> VS-FPM has several advantages for label-free digital pathology. Capture of complex image information simplifies model training and allows post-capture refocusing. FPM images combine high resolution with a large field of view, and the hardware is low-cost and compatible with many existing brightfield microscope systems. <b>Introduction:</b> By generating realistic histologically stained images from label-free image data, virtual staining (VS) methods have the potential to streamline clinical workflows, improve image consistency, and enable new ways of visualizing and analyzing histological tissues. <b>Methods:</b> We trained a conditional generative adversarial network to translate high-resolution FPM images of unstained tissues to brightfield H&E images and assessed the method using diagnosis of colonic polyps as a test case. <b>Results:</b> We found no statistically significant difference between the spatial resolution of FPM images captured at 4× magnification and images from a pathology slide scanner at 20× magnification. Visual assessment and image similarity metrics showed that VS-FPM images of unstained tissues closely resemble images of chemically H&E-stained tissues. However, the spatial resolution of virtual H&E images was approximately 20% lower than equivalent images of chemically stained tissues. Using VS-FPM, board-certified pathologists were able to accurately distinguish normal from dysplastic tissues and derive correct pathological diagnoses. <b>Conclusion:</b> VS-FPM is a reliable, accessible VS method that also overcomes many other limitations inherent to histopathology microscopy.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0206"},"PeriodicalIF":7.7,"publicationDate":"2025-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12669476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145672863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-11-27eCollection Date: 2025-01-01DOI: 10.34133/bmef.0202
Salleh Sonko, Mohamed Islam Houssam, Kossi Dodzi Bissadu, Brian O'Connor, Gahangir Hossain
{"title":"Scoping the Landscape of Deep Learning for Alzheimer's Disease Stage Classification: Methods, Challenges, and Opportunities.","authors":"Salleh Sonko, Mohamed Islam Houssam, Kossi Dodzi Bissadu, Brian O'Connor, Gahangir Hossain","doi":"10.34133/bmef.0202","DOIUrl":"10.34133/bmef.0202","url":null,"abstract":"<p><p>Deep learning (DL) models have been widely applied for Alzheimer's disease (AD) stage classification. This scoping review synthesizes recent research to evaluate current performance benchmarks, identify methodological limitations, and highlight translational barriers. DL has potential to augment diagnostic accuracy and accelerate early intervention in AD, but translation requires models that generalize across datasets and integrate into real-world clinical workflows. Following scoping review methodology, 18 peer-reviewed studies published between 2018 and 2024 were analyzed. We extracted dataset sources, preprocessing strategies, model architectures, performance metrics, and translational considerations. Most studies employed convolutional neural networks (CNNs) or transfer learning (TL) backbones with accuracies frequently reported above 90%. Comparative synthesis revealed that TL and custom CNNs achieved similar headline accuracies, with differences of less than one percentage point. Reported performance was highly sensitive to task framing (cross-sectional vs. progression) and dataset provenance, with curated subsets often yielding near-ceiling internal accuracies but limited generalizability. Only one study implemented true external validation, underscoring a critical translational gap. Cost-effectiveness was rarely discussed explicitly; however, several studies indicated that open datasets reduce financial barriers, while adapting pipelines for EMR, or multisite data entails substantial resource demands. DL for AD classification shows consistent high accuracy but limited robustness, with external validation and financial cost-effectiveness remaining underreported. Future progress depends on standardized evaluation protocols, explicit reporting of financial costs, and the development of clinically interpretable, workflow-integrated models.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0202"},"PeriodicalIF":7.7,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12657713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145650111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"mPEG@ELA-11 Alleviates Atherosclerosis via AKT-ER Stress-Mediated Macrophage Modulation.","authors":"Xiaoguang Li, Ning Dou, Linshan Zhong, Yicheng Wu, ZhenZhen Cai, Zaixu Zhao, Lefeng Qu, Qixia Jiang","doi":"10.34133/bmef.0203","DOIUrl":"https://doi.org/10.34133/bmef.0203","url":null,"abstract":"<p><p><b>Objective:</b> This study explores the role of methoxy polyethylene glycol@Elabela-11 (mPEG@ELA-11), a pH-responsive ELA-11 conjugate, in modulating macrophage function and attenuating atherosclerosis, focusing on the protein kinase B (AKT)-mediated endoplasmic reticulum (ER) stress pathway as a molecular target. <b>Impact Statement:</b> We reveal that ELA-11 alleviates atherosclerosis by suppressing macrophage foam cell formation, M1 polarization, and apoptosis via the AKT-ER stress pathway. We also develop mPEG@ELA-11, a novel pH-responsive nanocarrier, to enhance targeted drug delivery and therapeutic efficacy, offering a breakthrough for peptide-based cardiovascular nanomedicine. <b>Introduction:</b> Atherosclerosis, driven by macrophage dysfunction and lipid accumulation, is a major global killer. ELA-11, a fragment of Elabela peptide, shows cardiovascular protective effects, but its role in atherosclerosis and optimal delivery remain unstudied. <b>Methods:</b> Elabela mRNA (APELA) expression was analyzed in human carotid atherosclerotic plaques using real-time quantitative PCR analysis, and serum ELA levels were quantified via enzyme-linked immunosorbent assay in patients with carotid stenosis. In vitro studies on RAW264.7 macrophages evaluated mPEG@ELA-11 effects on oxidized low-density lipoprotein-induced foam cell formation, polarization, and apoptosis. In vivo efficacy was tested in ApoE<sup>-/-</sup> mice, comparing mPEG@ELA-11 with free ELA-11, and its pH-responsive release mechanism was characterized. <b>Results:</b> APELA was down-regulated in human atherosclerotic plaques, especially unstable lesions. mPEG@ELA-11 suppressed foam cell formation, M1 polarization, and apoptosis by inhibiting the AKT-ER stress pathway in vitro. In mice, it reduced plaque area more effectively than free ELA-11 attributed to pH-triggered release. <b>Conclusion:</b> The pH-responsive mPEG@ELA-11 alleviates atherosclerosis by modulating macrophages via the AKT-ER stress pathway, with favorable targeting and safety, representing a promising targeted peptide nanomedicine for atherosclerosis.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0203"},"PeriodicalIF":7.7,"publicationDate":"2025-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12645589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145643686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-09-30eCollection Date: 2025-01-01DOI: 10.34133/bmef.0181
Zhengxiang Huang, Lili Li, Kevin Dudley, Lan Xiao, Gary Huang, V Nathan Subramaniam, Chen Chen, Ross Crawford, Yin Xiao
{"title":"Three-Dimensional Dynamic Cell Models for Metabolic Dysfunction-Associated Steatotic Liver Disease Progression.","authors":"Zhengxiang Huang, Lili Li, Kevin Dudley, Lan Xiao, Gary Huang, V Nathan Subramaniam, Chen Chen, Ross Crawford, Yin Xiao","doi":"10.34133/bmef.0181","DOIUrl":"10.34133/bmef.0181","url":null,"abstract":"<p><p><b>Objective:</b> Metabolic dysfunction-associated steatotic liver disease (MASLD) is a complex, progressive disorder involving multiple cell types, ranging from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), characterized by pro-inflammatory macrophage activation, and can eventually advance to fibrosis, initiated by hepatic stellate cells (HSCs). In vitro multi-cell coculture models are vital tools for elucidating the mechanisms underlying MASLD. <b>Impact Statement:</b> Existing in vitro models for MASLD, including traditional 2-dimensional (2D) cultures and advanced organ-on-a-chip and organoid systems, face challenges in representing multiple cell types and analyzing them individually. Here, utilizing a cell carrier developed in our laboratory, we introduce a series of 3D dynamic coculture models that simulate different stages of MASLD progression and enable individual cell type analysis. <b>Introduction:</b> Currently, no single system provides an optimal balance of control, reproducibility, and analytical convenience. Most in vitro models lack the ability to isolate and analyze individual cell types post-culture, making it difficult to study cell-specific responses in MASLD progression. <b>Methods:</b> The 3D hollow porous sphere cell carrier allows cells to grow on its surface, while the culture device (mini-bioreactor) creates a dynamic environment. The 3 distinct MASLD models were established based on cocultured cell types: steatosis (hepatocytes only), MASH (hepatocytes and macrophages in a 4:1 ratio), and fibrosis (hepatocytes, macrophages, and HSCs in an 8:2:1 ratio). Well-established MASLD mouse models were employed to validate our in vitro 3D dynamic MASLD models, using 7-week-old male C57BL/6J mice fed a high-fat diet. <b>Results:</b> Our models demonstrate a progressive decline in hepatocyte viability and increased lipid accumulation, mirroring in vivo pathology. Additionally, gene expression profiles of our models align with those observed in MASLD-affected mouse livers. Notably, comparative analysis highlights the role of pro-inflammatory macrophages in disrupting hepatocyte lipid metabolism. <b>Conclusion:</b> These models offer a robust platform for investigating MASLD mechanisms and show potential for screening anti-MASLD therapeutics.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0181"},"PeriodicalIF":7.7,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12480745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145208576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-09-08eCollection Date: 2025-01-01DOI: 10.34133/bmef.0173
Zhenhao Hou, Xingdan Liu, Xianming Zhang, Ji Tan, Xuanyong Liu
{"title":"Construction of Silver-Calcium Micro-Galvanic Cell on Titanium for Immunoregulation Osteogenesis.","authors":"Zhenhao Hou, Xingdan Liu, Xianming Zhang, Ji Tan, Xuanyong Liu","doi":"10.34133/bmef.0173","DOIUrl":"10.34133/bmef.0173","url":null,"abstract":"<p><p><b>Objective:</b> This work aims to construct a functional titanium surface with spontaneous electrical stimulation for immune osteogenesis and antibacteria. <b>Impact Statement:</b> A silver-calcium micro-galvanic cell was engineered on the titanium implant surface to spontaneously generate microcurrents for osteoimmunomodulation and bacteria killing, which provides a promising strategy for the design of a multifunctional electroactive titanium implant. <b>Introduction:</b> Titanium-based implants are usually bioinert, which often leads to inflammation-induced loosening. Electrical stimulation has therapeutic potential; however, its dependence on external devices limits its clinical application. Therefore, designing an electroactive titanium surface with endogenous electrical stimulation capability is a promising strategy to overcome implant failure induced by inflammation. <b>Methods:</b> The silver-calcium micro-galvanic cell was constructed on titanium substrate surfaces by the ion implantation technique. RAW264.7 and MC3T3-E1 were used for cell culture studies with the material to evaluate immunomodulatory and osteogenic abilities of the implant. The expression levels of inflammatory genes and voltage-gated Ca<sup>2+</sup> channel-related genes were tested for investigating the mechanism of immunoregulation. The antibacterial properties of the modified titanium were assessed. Finally, its immunomodulatory effects in vivo were verified by a mouse subcutaneous inflammation model. <b>Results:</b> The silver-calcium micro-galvanic modified titanium surface generates microcurrents and releases Ca<sup>2+</sup>, which induces macrophage polarization toward the M2 phenotype and promotes osteogenic differentiation via paracrine signaling, exhibiting excellent antibacterial activity. <b>Conclusion:</b> The silver-calcium micro-galvanic cell on titanium could regulate the immune response to promote bone repair and exhibit antibacterial capabilities through noninvasive electrical stimulation, providing a promising strategy for the design of multifunctional electroactive implant surfaces.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0173"},"PeriodicalIF":7.7,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12415334/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-08-12eCollection Date: 2025-01-01DOI: 10.34133/bmef.0169
Edward J Jacobs, Julio P Arroyo, Manali Powar, Pedro P Santos, Irving Allen, Rafael Davalos
{"title":"Power-Driven Electroporation Is Predictive of Treatment Outcomes in a Conductivity-Independent Manner.","authors":"Edward J Jacobs, Julio P Arroyo, Manali Powar, Pedro P Santos, Irving Allen, Rafael Davalos","doi":"10.34133/bmef.0169","DOIUrl":"10.34133/bmef.0169","url":null,"abstract":"<p><p><b>Objective:</b> This study characterizes the effects of external conductivity on electroporation to develop methods to overcome potential patient-to-patient variability. <b>Impact Statement:</b> We demonstrate that constant power pulsed electric fields (PEFs) achieve consistent treatment outcomes despite variations in conductivity, thereby improving the predictability and efficacy of electroporation-based therapies. <b>Introduction:</b> Electropermeabilization-based therapies typically deliver static voltages between electrodes to induce cell permeabilization. However, tissue conductivity variations introduce uncertainty in treatment outcomes, as the tissue-specific electric field thresholds that induce electroporation also depend on the extracellular conductivity. <b>Methods:</b> Cell-laden hydrogels were fabricated with varying extracellular conductivities and treated with constant voltage PEFs. The voltages and currents were recorded to calculate the applied powers, and the reversible and irreversible electroporation thresholds were quantified using cell-impermeant and viability assays. Homogeneous and heterogeneous multi-tissue finite element models were employed to simulate the impact of tumor conductivity variability on the outcomes of reversible and irreversible electroporation for constant applied voltage, current, and power PEFs. Additionally, an in vivo murine pancreatic tumor model assessed the correlation between PEF delivery and treatment efficacy. <b>Results:</b> The In vitro experiments revealed that the electric field and current density thresholds were conductivity dependent, whereas the power density thresholds remained stable under variable conductivities. Computational modeling indicated that constant power PEFs best predicted tumor coverage in both homogeneous and heterogeneous multi-tissue models. Similarly, the in vivo tumor responses were also better predicted by applied power rather than voltage or current alone. <b>Conclusions:</b> Applying constant power PEFs enables consistent electroporation outcomes despite variations in conductivity.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0169"},"PeriodicalIF":7.7,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12343028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144838669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BME frontiersPub Date : 2025-08-07eCollection Date: 2025-01-01DOI: 10.34133/bmef.0159
Martha I González-Duque, Arielle Breuninger, Frédéric Leis, Julio B Michaud, Shaginth Sivakumar, Vincent Pautu, Marisa E Jaconi, Marc Jobin, Adrien Roux
{"title":"Tissue Engineering In Vitro Leaflet- and 3-Dimensional Printing-Based Implant Prototypes for Infant Mitral Valve.","authors":"Martha I González-Duque, Arielle Breuninger, Frédéric Leis, Julio B Michaud, Shaginth Sivakumar, Vincent Pautu, Marisa E Jaconi, Marc Jobin, Adrien Roux","doi":"10.34133/bmef.0159","DOIUrl":"10.34133/bmef.0159","url":null,"abstract":"<p><p><b>Objective:</b> This study engineers leaflet- and 3-dimensional (3D) printing-based implant prototypes for infant mitral valve repair via in vitro cultured mesoangioblasts isolated from the human fetal aorta (AoMAB). <b>Impact Statement:</b> Ultrahigh-molecular-weight polyethylene (UHMWPE) coatings, as well as 3D-printed gelatin methacrylate (GelMA) hydrogels for implants, represent new possibilities for devices used in mitral valve repair. <b>Introduction:</b> Mitral valve prolapse (MVP) repair in pediatric patients is challenging due to somatic growth, patient-prosthesis mismatch, reinterventions, infections, and thromboembolism. Tissue-engineered heart valves (TEHVs) offer potential solutions through conventional and 3D printing biofabrication. <b>Methods:</b> Four materials are evaluated: UHMWPE, UHMWPE coated with polyvinyl alcohol (PVA), UHMWPE coated with PVA and collagen, and 3D-printed GelMA hydrogels. The prototypes are characterized for micro/nanostructural, physicochemical (degradation, contact angle, Fourier transform infrared spectroscopy), and mechanical properties (simple strength tests, dynamic mechanical analysis) and assessed for cytocompatibility using AoMAB cells. A 3D printing mitral valve prototype is analyzed via immunostaining. <b>Results:</b> Results highlight UHMWPE coated with PVA and collagen as the most promising, with degradation (7.30 ± 18.71%), a hydrophilic contact angle (26.13 ± 1.45°), and biocompatibility (177.04 ± 68.92% viability). GelMA prototypes show superior viability (216.77 ± 77.69%) and scalability for 3D printing. <b>Conclusion:</b> UHMWPE coated with PVA and collagen and GelMA demonstrate strong potential for TEHVs, with AoMAB cells facilitating 3D culture and future personalized pediatric applications. Further in vitro validation and thrombogenicity assessments are needed.</p>","PeriodicalId":72430,"journal":{"name":"BME frontiers","volume":"6 ","pages":"0159"},"PeriodicalIF":7.7,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12329791/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144801061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}